Momenta Pharmaceuticals Initiates Phase I Clinical Study for M118 Subcutaneous Formulation

Momenta Pharmaceuticals, Inc. has initiated a Phase I study of a subcutaneous formulation of M118, its lead novel development candidate.

The study will evaluate the human safety, tolerability, bioavailability and pharmacokinetics of the compound.

M118 is a next-generation anticoagulant designed specifically for use in treating patients diagnosed with acute coronary syndromes (ACS).

M118 administered intravenously demonstrates superior efficacy to a standard dose of unfractionated heparin (UFH) in a preclinical model of acute arterial thrombosis.

This increase in efficacy did not result in an increased risk of bleeding.

It is anticipated that an important feature of M118 will be its flexibility in being formulated for both intravenous and subcutaneous administration to be most appropriate for individual ACS patients.

Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals, Inc.


DownloadFull Press Release

Latest News

MVM announces partial sale of its holding in Ambio

MVM Partners announces the partial sale of its holding in Ambio to The Carlyle Group

Alliance Pharma acquires Nizoral rights in APAC region

Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, is pleased to announce that it has agreed to acquire exclusive marketing rights to Nizoral, a medical, anti-dandruff shampoo brand, in Asia-Pacific from Janssen Pharmaceutica NV.

Alliance Pharma receives positive opinion for Diclectin

Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, announces that, following discussions with the Medicines and Healthcare products Regulatory Agency and the Commission on Human Medicines, the Marketing Authorisation Application for Diclectin® is now considered approvable.

Wilson Therapeutics AB announces public offer from Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc., has today, through Alexion Pharma Nordics Holding AB, announced a public cash offer to Wilson Therapeutics’ shareholders for a consideration of SEK 232 per Wilson Therapeutics share in cash (the “Offer”), which corresponds to a total offer value of approximately SEK 6,564 million, based on 28,292,272 shares outstanding.

Clinical study supports the use of Cheetah Medical's technologies

Cheetah Medical, a leader in non-invasive hemodynamic monitoring, has announced the publication of a major clinical study designed to evaluate stroke volume guided resuscitation in ICU patients with severe sepsis and septic shock

Vertos Medical Secures $28m in Latest Round of Funding

Vertos Medical Inc., a leader in the minimally invasive treatment of lumbar spinal stenosis has announced that it has completed a $28 million financing round.